In collaboration with Tulane University, U.S., CCHE57357’s proteomics and metabolomics unit recently posted a research paper that demonstrates the relation between the presence of two protein complexes and the resistivity against chemotherapy used in the treatment of thyroid cancer patients.
The study detected that some patients who suffered from thyroid cancer, were reported to have Arp2/3 complex and to have developed a high degree of aggressive resistance against Vemuraphenib chemotherapy. The goal is to understand the reasons for the poor response to this treatment, as the cancer cell when receiving this drug seeks to protect itself, by making changes in its protein structure, to help it resist the effect of the drug.
“Thanks to the promising technologies utilizing state of the art mass spectrometry made available at our lab in CCHE57357, we were able to reach such results , mentioned, Dr.Sameh Magdeldein, head of the proteomics and metabolomics research unit at CCHE57357.
Results of the study posted in the American Journal of cancer research of impact factor 6.1, may help in opening new venues for future treatment options.
It is noteworthy that the proteomics and metabolomics research unit is empowered with the most advanced and up-to-date technology to compete internationally and to produce high-quality scientific data aimed at identifying tumor-associated changes in the proteome and metabolome using a mass spectrometry-based open screening strategy.
for further information about the department: https://www.57357.org/en/department/proteomics-unit-dept/about-department/